摘要
目的:研究多药耐药相关蛋白-2(Multidrug resistance-associated protein2,MRP2)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法:采用免疫组织化学方法(I mmuno Histo Chemistry,I HC)检测47例手术切除的乳腺癌组织中MRP2的表达,并分析其与临床、病理特征的关系及对预后的影响。结果:MRP2在乳腺癌组织中的阳性表达率为85.1%(40/47),其中高表达者25例(53.2%);MRP2表达与月经状况、肿瘤大小、腋淋巴结转移、组织分级和激素受体状况均无关(P>0.05);Kaplan-Meier生存分析结果表明MRP2表达与无病生存期和总生存期均无关(P>0.05);COX多因素分析显示只有肿瘤大小和腋淋巴结转移和无病生存期和总生存期明显相关(P<0.05)。结论:MRP2在乳腺癌组织中具有一定的表达水平,但与乳腺癌患者预后无关。
Objective Intrinsic and/or acquired resistance was the major obstacle to overcome in the treatment of patients with brcast cancer. The aim of the present study was to investigate the relationship between the expression of multidrug resistance-associated protein 2 （MRP2） with the clinicpathologic characteristics and the prognosis in primary breast cancer patients. Methods Expression of MRP2 in 47 breast cancer patients was determined by immunohistochemistry on formalin-fixcd, paraffin-embedded tumor section. Results MRP2 expression was observed in 40 of 47（85. 1%）. No relation can be cstablished between expression o＇f MRP2 and other clinicopathologic parameters. Kaplan-Meier analyses revealed that MRP2 expression didn＇t associated with disease free survival （DFS） or overall survival（OS） （P〉0. 05）. In multivariate Cox regression analysis,tumor size and lymph node metastasis was independent prognostic factors for survival （P〈0.05）. Conclusion Our results suggested that MRP2 is frequently expression in primary breast cancer, but MRP2 is not a poor prognostic factor in patients with breast cancer.
出处
《实用医技杂志》
2006年第13期2185-2187,共3页
Journal of Practical Medical Techniques
基金
深圳市科技计划资助项目(编号:200204018)
关键词
乳腺肿瘤
基因
MDR
多药耐药相关蛋白-2
预后
Breast carcinoma Gene
MDR
Multidrug resistance-associated protein 2 （ MRP2 ）
Prognosis
